Read twice and referred to the Committee on Finance.
This bill amends Medicaid and Medicare drug pricing rules to codify and enable value-based purchasing arrangements (VBPAs). It permits multiple "best price" points for drugs sold under VBPAs if offered to all States, clarifies how outcome-triggered refunds or withheld payments count toward average manufacturer price (AMP) and average sales price (ASP), creates an antikickback exception for manufacturer payments to States under VBPAs, requires HHS guidance for inpatient VBPA use, and directs a GAO study with a report due June 30, 2029.
Progressives stress risks to Medicaid rebates and 340B; conservatives emphasize market flexibility.
Relative to its intended legislative type, this bill is a primarily substantive statutory package that codifies and modifies how value-based purchasing arrangements interact with Medicaid drug pricing and related federal program calculations, while also adding a targeted anti-kickback exception and requiring administrative guidance and a GAO study.
This bill amends Medicaid and Medicare drug pricing rules to codify and enable value-based purchasing arrangements (VBPAs).
It permits multiple "best price" points for drugs sold under VBPAs if offered to all States, clarifies how outcome-triggered refunds or withheld payments count toward average manufacturer price (AMP) and average sales price (ASP), creates an antikickback exception for manufacturer payments to States under VBPAs, requires HHS guidance for inpatient VBPA use, and directs a GAO study with a report due June 30, 2029.
The bill also mandates HHS and HHS-OIG rulemaking within 180 days to implement several provisions.
Plausible as part of broader bipartisan reform package but standalone it faces stakeholder pushback and fiscal scrutiny; outcome depends on negotiations and inclusion in larger legislation.
Relative to its intended legislative type, this bill is a primarily substantive statutory package that codifies and modifies how value-based purchasing arrangements interact with Medicaid drug pricing and related federal program calculations, while also adding a targeted anti-kickback exception and requiring administrative guidance and a GAO study. The statutory edits are concrete and targeted, and responsibilities and deadlines are assigned for implementation.
Progressives stress risks to Medicaid rebates and 340B; conservatives emphasize market flexibility.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress risks to Medicaid rebates and 340B; conservatives emphasize market flexibility.
Likely cautiously supportive of using value-based contracts to expand access to high-cost or transformative therapies, because VBPs can link payment to outcomes.
However, there are concerns that changes to best-price and rebate reporting could reduce Medicaid savings or weaken programs like 340B, so support would be conditional on safeguards and transparency.
The GAO study and required guidance are viewed positively but may be seen as delayed oversight.
Generally favorable toward clarifying rules to enable value-based drug contracts, seeing them as pragmatic tools to control costs and improve outcomes.
Will weigh evidence about fiscal impact and implementation complexity, welcoming the GAO study and 180-day rulemaking deadlines.
Support will hinge on monitoring whether rebate mechanics undermine federal/state budgets.
Likely supportive because the bill reduces regulatory uncertainty and enables market-driven, value-based payment models.
The antikickback exception and allowance for multiple best-price points are seen as removing barriers manufacturers face in offering outcome-based contracts.
Skepticism may remain about federal costs, but overall the bill is viewed as pro-innovation and flexible.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Plausible as part of broader bipartisan reform package but standalone it faces stakeholder pushback and fiscal scrutiny; outcome depends on negotiations and inclusion in larger legislation.
The bill has not accumulated any surfaced votes yet.
Progressives stress risks to Medicaid rebates and 340B; conservatives emphasize market flexibility.
Plausible as part of broader bipartisan reform package but standalone it faces stakeholder pushback and fiscal scrutiny; outcome depends on…
Relative to its intended legislative type, this bill is a primarily substantive statutory package that codifies and modifies how value-based purchasing arrangements interact with Medicaid drug pricing and related federa…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.